Company intelligence / Profile preview
Elevar Therapeutics
Fort Lee, New Jersey, United Stateselevartherapeutics.com ↗
- Ownership
- Private
- Employees
- ~109
- Development stage
- NDA
01
Overview
Elevar’s lead program is rivoceranib, an oral TKI targeting VEGFR2. In combination with camrelizumab, it has completed Phase III trials as first-line treatment for unresectable hepatocellular carcinoma. The FDA accepted the NDA with a PDUFA date set for May 2024. Rivoceranib has been tested in over 6,000 patients globally and received Orphan Drug Designation in multiple regions. Apealea®, a non-Cremophor EL formulation of paclitaxel, is approved in Europe for ovarian cancer and available via named patient programs elsewhere
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (e.g., rivoceranib)Cytotoxic drugs (e.g., paclitaxel micellar/Apealea®)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Hengrui Pharma – partner on camrelizumab development/commercializationTanner Pharma Group – global named patient access program partner for Apealea®
Beyond the preview
Go deeper on Elevar Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elevar Therapeutics.